Needle your thoughts about Management applying to the FDA for a Paxalisib Fast Track review. James Garner was aware of the article confirming that DB 102 (enzastaurin) lead candidate received FDA Fast Track designate for the treatment of newly diagnosed glioblastoma in July 2020, and confirmed it is on Kazia's radar.
https://newsfilter.io/articles/denovo-biopharmas-enzastaurin-fast-trackd-for-brain-tumor-52f02c3931cd83c5f392b1916b671c98
Regards.
Add to My Watchlist
What is My Watchlist?